Business Context and Reporting Period
This Form 8-K Current Report was filed by Madrigal Pharmaceuticals, Inc. (MDGL) on March 11, 2025, covering events occurring on March 9, 2025, and March 10, 2025. The filing addresses changes to the composition of the Board of Directors.
Key Financial Metrics
This filing does not report operational financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to director compensation:
- Annual Cash Fee: $50,000 for the new director.
- Committee Fees: $12,500 for the Audit Committee and $6,000 for the Nominating and Governance Committee.
- Equity Grant: $600,000 total value (50% stock options, 50% restricted stock units).
Material Changes
The filing reports the following material changes to corporate governance:
- Resignation: Fred Craves, Ph.D., resigned from the Board of Directors, effective July 1, 2025. The resignation was not due to any disagreement with the Company.
- Board Expansion: The Board size increased from nine to ten members.
- New Election: Jackie Fouse, Ph.D., was elected as a Class III director to fill the vacancy. She is expected to join the Audit and Nominating and Governance Committees.
Outlook, Risks, and Unusual Items
The filing contains no guidance, outlook, or discussion of risks and contingencies. The departure of Dr. Craves is explicitly stated as amicable. The appointment of Dr. Fouse includes standard indemnification agreements and a vesting schedule for her equity grant tied to continued service.
Investor Verification Checklist
- Verify the effective date of Dr. Craves' resignation (July 1, 2025) and the interim status of the Board.
- Confirm Dr. Fouse's specific committee assignments and voting rights as a Class III director.
- Review the vesting schedule details for the $600,000 equity grant to understand future dilution impacts.
- Check for any subsequent filings regarding the annual meeting where Dr. Fouse will stand for re-election.